4D Molecular Therapeutics (FDMT) Retained Earnings (2019 - 2026)
4D Molecular Therapeutics (FDMT) reported Retained Earnings of -$785.1 million for Q1 2026, down 25.78% year-over-year from -$1.1 billion in Q1 2025, and down 9.6% quarter-over-quarter from -$716.3 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Retained Earnings (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 8 years of Retained Earnings data on file, last reported at -$785.1 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$785.1 million, down 25.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$785.1 million (down 25.78% YoY), and the FY2025 annual result was -$716.3 million, down 24.32% from the prior year.
- Retained Earnings fell to -$785.1 million in Q1 2026 per FDMT's latest filing, from -$716.3 million in the prior quarter.
- Over five years, Retained Earnings peaked at $534000.0 in Q3 2023 and troughed at -$785.1 million in Q1 2026.
- A 5-year average of -$333.5 million and a median of -$372.8 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings jumped 128.85% in 2023, then plunged 572530.28% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$1.2 million in 2022, then plunged by 34626.34% to -$415.3 million in 2023, then plunged by 38.73% to -$576.2 million in 2024, then dropped by 24.32% to -$716.3 million in 2025, then fell by 9.6% to -$785.1 million in 2026.
- Business Quant data shows FDMT's Retained Earnings at -$785.1 million in Q1 2026, -$716.3 million in Q4 2025, and -$735.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -785.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -785.10 Mn |
| Dec 31, 2025 | -716.30 Mn |
| Sep 30, 2025 | -735.70 Mn |
| Jun 30, 2025 | -678.83 Mn |
| Mar 31, 2025 | -624.17 Mn |
| Dec 31, 2024 | -576.20 Mn |
| Sep 30, 2024 | -526.52 Mn |
| Jun 30, 2024 | -293,000.00 |
| Mar 31, 2024 | -109,000.00 |
| Dec 31, 2023 | -415.33 Mn |
| Sep 30, 2023 | 534,000.00 |
| Jun 30, 2023 | -372.79 Mn |
| Mar 31, 2023 | -270,000.00 |
| Dec 31, 2022 | -1.20 Mn |
| Sep 30, 2022 | -1.85 Mn |
| Jun 30, 2022 | -1.83 Mn |
| Mar 31, 2022 | -233.33 Mn |
| Dec 31, 2021 | -207.00 Mn |
| Sep 30, 2021 | -181.90 Mn |
| Jun 30, 2021 | -159.67 Mn |